公司資料
BioAtla, Inc. 股價、新聞與催化劑
- 股票代碼:
- BCAB
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
3.18 USD (0.00%)
收盤價
最後更新: 2026年8月21日
5.85M USD
市值
股價為何變動
As of Aug 21, 2026, BCAB was little changed and closed at $3.18. No new same-company headline was identified in the current news window.
公司概覽
Conditionally Active Biologics
BioAtla develops antibodies engineered to bind preferentially under conditions found in the tumor microenvironment. The CAB platform uses factors such as acidic pH to reduce target binding in normal tissue and potentially limit on-target, off-tumor toxicity.
BA3182
BA3182 is a conditionally active EpCAM and CD3 bispecific T-cell engager in Phase 1 development for advanced adenocarcinomas. Both binding arms are designed to activate preferentially within tumors.
Antibody-Drug Conjugates
The clinical ADC portfolio includes ozuriftamab vedotin against ROR2 and mecbotamab vedotin against AXL. Programs have been studied in oropharyngeal cancer, sarcoma and KRAS-mutant lung cancer.
Broader CAB Pipeline
Evalstotug is a conditionally active CTLA-4 antibody, while preclinical assets target Nectin-4, B7H4, B7H3, EGFR and Trop2. BioAtla is evaluating strategic transactions and may alter the pace or scope of these programs while preserving capital.
未來催化劑
- BioAtla’s catalysts are conditional-activation antibodies and any oncology update that shows the platform can still differentiate. The company remains data-sensitive because the platform story is not yet fully proven.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。